AB SCIEX, a global leader in life science analytical technologies, recently opened its new Asia Pacific Application and Training Centre. Located in Singapore's biomedical hub at Biopolis, this center provides comprehensive service, support and application development to enable the scientific community in Singapore and the rest of ASEAN, Australia, New Zealand, Japan and Korea to increase use of mass spectrometry (MS) technologies for a broad range of applications. The new Singapore facility complements the regional application support center that AB SCIEX opened last year in Shanghai, China.

Also, AB SCIEX has broadened its chromatography solutions portfolio with new ultra-high performance liquid chromatography (UHPLC) solutions. This expansion includes the introduction of the Eksigent ekspert ultraLC 100 and 100-XL systems, which are analytical flow LC systems that enhance AB SCIEX's complete LC/MS/MS workflow solutions. The new Eksigent ekspertTM ultraLC 100 and 100-XL systems are designed for a wide range of scientists, including food safety, clinical research and forensic scientists, who need a total workflow solution for high-throughput UHPLC-MS/MS analysis of residues, impurities, drugs and other analytes in complex matrices.

In an interview with BioSpectrum, Mr Johnson Ho, vice president- APAC sales, AB SCIEX, shares his views on the Asian market and the demand for mass spectrometry products.

AB SCIEX recently launched a series of new mass spectrometry technology with the objective to set a new benchmark in the industry. What kind of feedback have you received from the Asian market?

Mr Ho: Our customers in Asia are responding very enthusiastically to the launch of our new AB SCIEX 4500 series of mass spectrometers, Eksigent ekspert ultraLC 100 series and the new Eksigent micro LC 200 system. The feedback we are getting is that our new mass spectrometry and LC systems deliver on our promise of simplifying the adoption of LC/MS/MS across Asia. AB SCIEX is a trusted partner with many important scientific laboratories throughout APAC, and yet we are still at the tip of the huge potential for our LC/MS/MS technology to improve life in Asia-Pacific.

The AB SCIEX technology is central to the drug discovery and development pipeline. From the rapid structural identification and in vitro metabolic stability needs of the early discovery phase to the integrated Qual/Quant and low-level quantitation requirements of the development phase, AB SCIEX offers an innovative set of chromatography, mass spectrometry, software and compliance and validation solutions.